Myasthenia Gravis Disease Market In-Depth Analysis Globally by Top Key Players
The surging cases of neuromuscular disorders are estimated
to favor the market growth globally. Myasthenia gravis is referred to as a
neuromuscular disorder which results in the skeletal muscles to weaken. The
disease generally occurs due to the impairment of communication between the
nerve cells and the muscles and causes difficulty in the relaxation and
contraction of muscles. The antibodies present in the body destroy the receptor
for acetylcholine at the neuromuscular joint which prevents the muscles from
contracting and performing its normal function. Market Research Future (MRFR)
proclaims that the global myasthenia
gravis disease market is estimated to garner 7.5% CAGR during the forecast
period (2017-2023).
Market Potential and Pitfalls
Myasthenia Gravis can occur both in females and males but
usually affect the women under 40 years and the aging population from 50 to 70
years. With surging cases of neuromuscular disorders, a growing number of
clinical facilities, and raising awareness regarding the treatment line, the
global myasthenia gravis disease is considered to receive a boost. The
increasing occurrences of autoimmune disorders, rising spending on healthcare,
and a strong pipeline in the treatment are some of the factors contributing to
the growth of the market. The surging cases of myasthenia gravis can impact the
quality of life, which further fosters its growth. With the growth in R&D
activities, the myasthenia gravis disease market is likely to experience a
thrust. Moreover, the rising adoption of novel therapies coupled with the
favorable reimbursement policies especially in the developed economies has
promoted its growth worldwide.
On the contrary, the ignorance symptoms and signs coupled
with the high cost of treatment are some of the top barriers vitiating the
market growth across the globe. Moreover, the limited availability of FDA
approved drugs is estimated to deter the market growth in the long run.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5843
Global Myasthenia Gravis Disease Market: Segmental
Analysis
The global myasthenia gravis disease market has been
segmented on the basis of treatment, diagnosis, and end-user.
By mode of diagnosis, the global myasthenia gravis disease
market has been segmented into blood tests, imaging, edrophonium tests,
electrodiagnostic, pulmonary function tests, and others.
By mode of treatment, the global myasthenia gravis disease
market has been segmented into surgery, medication, plasmapheresis and
intravenous immunoglobulin, autologous Hematopoietic Stem Cell Transplantation
(HSCT), and others.
By mode of end-users, the global myasthenia gravis disease
market has been segmented into clinics, hospitals, academic research
institutes, and others.
Reginal Insights
Geographically, the myasthenia gravis disease market span
across regions namely, Europe, America, Asia Pacific, and the Middle East and
Africa.
Considering the global scenario, the American region is
estimated to command the largest market share. The growth is ascribed to the
surging number of drug manufacturers, increased government funding for the
treatment, and growing awareness regarding the long-term effects of muscle
dystrophy. Major companies in this region are launching FDA approved drugs
which have augmented the commercial access to such drugs on a global scale.
The European region is considered to occupy the second spot
and is likely to retain its pole position in the long run. The growth can be
ascribed to the adoption of the latest therapies, high availability of advanced
treatment facilities, and the presence of skilled medical professionals.
The Asia Pacific region is estimated to be the fastest
growing region due to the presence of a large geriatric population base
especially in economies like China and Japan. The surging awareness regarding
the long-term effects of muscular dystrophies has further contributed to the
market growth. Moreover, the rising awareness regarding neuromuscular disorders
coupled with the vast improvement made in the healthcare sector in economies
like China, India, Malaysia, and Indonesia has further influenced the market
growth to a large extent.
Industry Updates
April 01, 2019: Ra Pharmaceuticals, Inc. has recently
declared that the data from its Phase 2 clinical trial of zilucoplan for
treating generalized myasthenia gravis has been selected for an Emerging
Science dual oral and poster presentation at the American Academy of Neurology
Annual Meeting in Philadelphia, 2019.
Competitive Dashboard
The prominent players operating in the global myasthenia
gravis disease market comprises AbbVie Inc. (U.S.), F. Hoffmann Roche La Ltd.
(Switzerland), Biogen Inc. (U.S.), Fresenius Kabi (Germany), Cipla (India), Sun
Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Apotex
Corporation (Canada), RPG Life Sciences (India), Teva Pharmaceutical Industries
Ltd. (Israel), Bristol-Myers Squibb Company (U.S.), Valeant Pharmaceuticals
International (U.S.), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline
plc (UK), and others.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment